Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAL-85-1 | TNBC | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15280.203 | 0.0351 | -0.9808 | 0.7211 | |
| CAL-85-1 | TNBC | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15280.203 | 0.0351 | -0.9808 | 0.7211 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5911.074 | 0.9434 | 0.8996 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5911.074 | 0.9434 | 0.8996 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5911.074 | 0.8461 | 0.7254 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5911.074 | 0.8461 | 0.7254 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5911.074 | 0.9043 | 0.8299 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5911.074 | 0.9043 | 0.8299 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5911.074 | 0.7041 | 0.4669 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5911.074 | 0.7041 | 0.4669 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5911.074 | 0.1483 | -0.6297 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5911.074 | 0.1483 | -0.6297 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5911.074 | 0.0733 | -0.8012 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5911.074 | 0.0733 | -0.8012 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5911.074 | 0.0502 | -0.8579 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5911.074 | 0.0502 | -0.8579 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5911.074 | 0.0198 | -0.9374 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5911.074 | 0.0198 | -0.9374 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5911.074 | 0.0168 | -0.9460 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5911.074 | 0.0168 | -0.9460 | 1.1317 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5912.074 | 1.0451 | 1.0977 | 0.9249 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5912.074 | 1.0451 | 1.0977 | 0.9249 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5912.074 | 0.9605 | 0.9147 | 0.9249 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5912.074 | 0.9605 | 0.9147 | 0.9249 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5912.074 | 1.0206 | 1.0446 | 0.9249 |